Trends in Molecular Medicine

Translating basic cancer research into new cancer therapeutics
pp. 1-9(9)
Authors: Workman P.; Kaye S.B.

Histone modification: the 'next wave' in cancer therapeutics
pp. 10-11(2)
Author: Chung D.

Aromatase inhibitors continue their ATAC on tamoxifen
pp. 12-13(2)
Author: Nicholls H.

STI571 (Gleevec&unknown;) as a paradigm for cancer therapy
pp. 14-18(5)
Author: Druker B.J.

The ErbB receptor family: a therapeutic target for cancer
pp. 19-26(8)
Authors: de Bono J.S.; Rowinsky E.K.

Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention
pp. 27-31(5)
Authors: Herrera R.; Sebolt-Leopold J.S.

Complexities in the development of cyclin-dependent kinase inhibitor drugs
pp. 32-37(6)
Author: Sausville E.A.

Therapeutic exploitation of the p53 pathway
pp. 38-42(5)
Authors: Lane D.P.; Lain S.

Epigenomics and epigenetic therapy of cancer
pp. 43-48(6)
Authors: Brown R.; Strathdee G.

Proteasome inhibition: a novel approach to cancer therapy
pp. 49-54(6)
Author: Adams J.

Hsp90 inhibitors as novel cancer chemotherapeutic agents
pp. 55-61(7)
Author: Neckers L.

HIF-1 and tumor progression: pathophysiology and therapeutics
pp. 62-67(6)
Author: Semenza G.L.

The emerging fields of suicide gene therapy and virotherapy
pp. 68-73(6)
Authors: Kirn D.; Niculescu-Duvaz I.; Hallden G.; Springer C.J.

APP on the move
pp. 152-155(4)
Authors: Muller U.; Kins S.

A cut above the rest?
pp. 157-158(2)
Authors: McMichael J.W.; Dransfield I.; Sallenave J.-M.

Gene expression profiling to predict lymphoma outcome
pp. 159-159(1)
Author: Ramsay M.

GNAS1 imprinting: the latest twist
pp. 159-160(2)
Author: Aldred M.

In brief
pp. 160-161(2)
Authors: Weitzman J.; O'Neill P.

Interleukin-5 and eosinophils as therapeutic targets for asthma
pp. 162-167(6)
Authors: Foster P.S.; Hogan S.P.; Yang M.; Mattes J.; Young I.G.; Matthaei K.I.; Kumar R.K.; Mahalingam S.; Webb D.C.

Molecular basis of cholesterol homeostasis: lessons from Tangier disease and ABCA1
pp. 168-173(6)
Author: Oram J.F.

The coming of age of 1,25-dihydroxyvitamin D₃ analogs as immunomodulatory agents
pp. 174-179(6)
Authors: Mathieu C.; Adorini L.

Caretaker tumour suppressor genes that defend genome integrity
pp. 179-186(8)
Authors: Levitt N.C.; Hickson I.D.

Carbohydrate-binding proteins in cancer, and their ligands as therapeutic agents
pp. 187-192(6)
Authors: Nangia-Makker P.; Conklin J.; Hogan V.; Raz A.

The Dictionary of Gene Technology (2nd edition): A landmark research tool for the post-genomic era
pp. 193-193(1)
Author: Gurwitz D.